- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
RPG Life Sciences reported H1 FY26 revenue of 350.6 Cr, up 3.8% year-over-year (YoY), with Q2 revenue growing 5.5% YoY to 181.7 Cr. However, profit after tax (PAT) saw a 6.0% YoY decline in H1 to 54.8 Cr and a 9.6% decline in Q2 to 28.5 Cr, indicating margin pressure. Domestic Formulations (DF) was a key driver, surging 13.5% YoY to 246.1 Cr (71% of H1 sales), fueled by new products in specialty and chronic segments. International Formulations grew modestly at 2.1%. The API segment experienced a significant 34.2% decline due to a fire incident. The company remains debt-free.
Management is actively pursuing strategies to transform brands like Naprosyn (targeting 100 Cr+) and Immunosuppressants (aiming for 200 Cr+), along with building its MABs portfolio. Strategic focus areas include expanding global reach through new geographies and product launches for APIs, and enhancing overall manufacturing productivity. The company has invested 140 Cr in capital expenditure since FY22 for modernizing plants and is evaluating M&A opportunities and a strong digital roadmap to fuel future growth.